NEWS
AIM Meningococcus Polysaccharide Vaccine Obtained Approval for Clinical Trial
News by ET Net (Dec 2): AIM Vacin, a
wholly-owned subsidiary of AIM Vaccine, obtained the approval from the National
Medical Products Administration yesterday (December 1) for carrying out
clinical trials of ACYW135 Meningococcus Conjugate Vaccine (MCV4).
Previous：It's already the first one
Next：Another Significant Progress in Delta-specific COVID Vaccine Development—Rong’an Bio Begun Rolling Submission to CDE
